RANCHO CORDOVA, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Philip Coehlo, chief technology officer of Cesca’s device subsidiary, Thermogenesis, will be presenting at the Advanced Cell Therapy Shanghai Summit 2017 (ACTSS2017), taking place November 16-17 at the Grand Hyatt Shanghai. Cesca Therapeutics is an affiliated company of China-based Boyalife Group.
Mr. Coehlo’s presentation, entitled “Next Generation of Automated Closed CAR-T Biomanufacturing Systems,” is scheduled for 10:30-10:45 a.m. local time on November 16th, in Crystal Ballroom II.
For more information about Advanced Cell Therapy Shanghai Summit 2017: https://actss.org/
About the Advanced Cell Therapy Shanghai Summit 2017
The Advanced Cell Therapy Shanghai Summit 2017 is a leading gathering of regulatory experts, key opinion leaders, industry executives, manufacturers, investors and legal and finance professionals in the area of advanced cell therapeutics, from around the world.
About Boyalife Group
Founded in 2009 as the International Consortium of Stem Cell Research (INCOSC), Boyalife Group is a privately-held global biopharmaceutical holding company with 30 subsidiaries and affiliated companies operating in three distinct business segments: 1) cellular processing and biobanking for regenerative medicine, CAR-T and other emerging immunotherapies, 2) genomics and 3) drug discovery. Boyalife Group is headquartered in Wuxi City, China, and maintains operations in Tianjin, Guangzhou, Beijing, Seoul, South Korea, New Delhi, India and Sacramento, California, USA.
About Cesca Therapeutics Inc.
Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets.
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics’ annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Cesca Therapeutics Inc.